Open AccessAssociations of Gene Polymorphisms and Prognosis in Highly Adherent to Treatment Patients After Myocardial Infarction
Author(s) -
К. Г. Переверзева,
С. С. Якушин,
Alexander A. Nikiforov,
А. А. Новоселова
Publication year - 2021
Publication title -
arhivʺ vnutrennej mediciny
Language(s) - English
Resource type - Journals
eISSN - 2411-6564
pISSN - 2226-6704
DOI - 10.20514/2226-6704-2021-11-5-380-388
Subject(s) - cyp2c19 , p2y12 , medicine , clopidogrel , myocardial infarction , genotype , pharmacogenetics , gene polymorphism , clinical endpoint , allele , polymorphism (computer science) , pharmacology , oncology , gene , bioinformatics , cardiology , genetics , biology , randomized controlled trial , cytochrome p450 , metabolism
Aim . To evaluate the influence of genetic factors on the risk of developing a combined endpoint, during a one-year supervision of patients, who had myocardial infarction and highly adherent to drug therapy. Material and methods . The research included 250 patients with high adherence to treatment with myocardial infarction, using the method of polymerase chain reaction we determined the polymorphisms Thr174Met and Met235Thr in the AGT gene, Arg389Gly and Ser49Gly in the ADRB1 gene, Ser447Ter in the LPL gene and Leu28Pro in the APOE gene, Trp212Ter and G681A in the CYP2C19 gene, and then we evaluated their influence on the prognosis. Results. A significant influence on the risk of developing combined endpoint was noticed for the polymorphism of CYP2C19 (G681A) gene. For the GA genotype of the CYP2C19 gene (G6881A), the OR of developing an unsuccessful outcome was 1.97 (95 % CI 1.05 — 3.69) (P = 0.03). For сarrier-state of A allele the OR was 1.46 (95 % CI 1.06 — 3.64) (P = 0.03). Conclusion . The results received indicate the need for individual approach for the choice of drugs from the group of inhibitors P2Y12-receptors for dual antiplatelet therapy, and if clopidogrel is chosen it is necessary to resolve the issue of pharmacogenetic testing for CYP2C19.